Key result
Early ICD implantation in high-risk patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention demonstrated a beneficial impact on all-cause mortality at 3 years.
Why the study?
A dynamic and robust model of dichotomised sudden cardiac death risk assessment after primary PCI is lacking, highlighting the need to refine guideline-based primary prevention criteria.
Does prophylactic ICD implantation improve survival in patients with ischaemic cardiomyopathy and severely reduced LVEF post-primary PCI for STEMI?
Does prophylactic ICD implantation improve survival in patients with ischaemic cardiomyopathy and severely reduced LVEF post-primary PCI for STEMI?
Answers are grounded in this paper and cite their sources.
This review highlights the DAPA trial's novel perspectives on early SCD risk assessment and prophylactic ICD implantation in STEMI patients treated with primary PCI.
In patients with ischaemic cardiomyopathy and severely reduced left ventricular ejection fraction (LVEF), an arrhythmogenic milieu is created by a complex interplay between myocardial scarring (assessed by cardiac MRI) and multiple other factors (ventricular ectopy, ischaemia and autonomic imbalance), favouring the occurrence of arrhythmic sudden cardiac death (SCD). Currently, a dynamic and robust model of dichotomised SCD risk assessment after primary percutaneous coronary intervention (PCI) is lacking, underlining the urgent need for further refinement of the widely accepted and guidelines-based criteria (ischaemic cardiomyopathy, LVEF ≤35%) for primary prevention. This review addresses the potential additional value of the recently published Defibrillator After Primary Angioplasty (DAPA) trial results. The DAPA trial conveys important messages and provides novel perspectives regarding left ventricular function post-primary PCI as an (early) risk marker for SCD and the impact of prophylactic ICD implantation on survival in this cohort. In the context of other previous primary prevention trials, DAPA was the first trial including only ST-elevation MI patients all treated with acute PCI.
No takes yet. Share an insight, caveat, or question.
Haanschoten et al. (2021) conducted a review in ST-elevation myocardial infarction (STEMI) treated with primary PCI (n=266). Early ICD implantation vs. Optimal medical therapy was evaluated on All-cause mortality after 3 years. Early ICD implantation in high-risk patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention demonstrated a beneficial impact on all-cause mortality at 3 years.
Synapse has enriched 10 related papers. Consider them for comparative context: